WO2004091546A3 - Central nervous system stimulant and opioid antagonist combinations - Google Patents

Central nervous system stimulant and opioid antagonist combinations Download PDF

Info

Publication number
WO2004091546A3
WO2004091546A3 PCT/US2004/009161 US2004009161W WO2004091546A3 WO 2004091546 A3 WO2004091546 A3 WO 2004091546A3 US 2004009161 W US2004009161 W US 2004009161W WO 2004091546 A3 WO2004091546 A3 WO 2004091546A3
Authority
WO
WIPO (PCT)
Prior art keywords
opioid antagonist
nervous system
central nervous
system stimulant
antagonist combinations
Prior art date
Application number
PCT/US2004/009161
Other languages
French (fr)
Other versions
WO2004091546A2 (en
Inventor
Robert Kaiko
Iwona Beczkowska
Original Assignee
Euro Celtique Sa
Robert Kaiko
Iwona Beczkowska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa, Robert Kaiko, Iwona Beczkowska filed Critical Euro Celtique Sa
Publication of WO2004091546A2 publication Critical patent/WO2004091546A2/en
Publication of WO2004091546A3 publication Critical patent/WO2004091546A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Abstract

Disclosed in certain embodiments is a pharmaceutical composition comprising at a CNS stimulant and an opioid antagonist.
PCT/US2004/009161 2003-03-31 2004-03-25 Central nervous system stimulant and opioid antagonist combinations WO2004091546A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45894003P 2003-03-31 2003-03-31
US60/458,940 2003-03-31

Publications (2)

Publication Number Publication Date
WO2004091546A2 WO2004091546A2 (en) 2004-10-28
WO2004091546A3 true WO2004091546A3 (en) 2005-03-24

Family

ID=33299655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009161 WO2004091546A2 (en) 2003-03-31 2004-03-25 Central nervous system stimulant and opioid antagonist combinations

Country Status (1)

Country Link
WO (1) WO2004091546A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005033543A1 (en) * 2005-07-14 2007-01-18 Grünenthal GmbH A fragrance-containing transdermal therapeutic system
DE102006015734A1 (en) * 2006-04-04 2007-10-11 Hermann, Holger Lars, Dr. Combination preparations of modafinil, ritalin and topiramate and their derivatives for the treatment of cocaine addiction and / or impulse control disorder
FR2899476B1 (en) * 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris ASSOCIATION OF MAZINDOL IN THE TREATMENT OF DEFICIT ATTENTION / HYPERACTIVITY
DE102007024428A1 (en) * 2007-05-25 2008-11-27 Hermann, Holger Lars, Dr. med. Use of naloxone for producing a medicament devoid of non-oral abuse-potential for humans, where the medicament contains a psychotropic substance, which is useful for treating attention deficit hyperactivity disorder
WO2011020030A2 (en) 2009-08-13 2011-02-17 The General Hospital Corporation Methods and compositions to prevent addiction
ES2925951T3 (en) * 2015-07-22 2022-10-20 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for its use
WO2022251683A1 (en) * 2021-05-27 2022-12-01 Allen Gregory Seth Weight loss formulation and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604198A (en) * 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5604198A (en) * 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents

Also Published As

Publication number Publication date
WO2004091546A2 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
AU2003261723A1 (en) Cxcr4 antagonist and use thereof
AU2003302603A1 (en) Improved opioid pharmaceutical compositions
AU4859001A (en) Method of evaluating queries against received event information
AU2003272601B2 (en) Sustained-release opioid formulations and methods of use
IL168056A0 (en) Selected cgrp antagonists, method for production and use thereof as medicament
PL376373A1 (en) Selected cgrp antagonists, method for production and use thereof as medicament
PL1680403T3 (en) Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
AU2003288994A1 (en) Nitrogen-containing heterocyclic compounds and medicinal use thereof
HK1072559A1 (en) Methods and dosage forms for controled delivery ofpaliperidone
AP2002002617A0 (en) Tamper-resistant oral opioid agonist formulation
PT2425821T (en) Pharmaceutical preparation containing oxycodone and naloxone
IL180928A0 (en) Multiparticulates of preferably an opioid, and method of manufacturing using extrusion
HK1080471A1 (en) Secondary amino anilinic piperidines as mch1 antagonists and uses thereof
ZA991745B (en) Combination of a selective NMDA NR2B antagonist and an opioid analgesic.
AU2001251083A1 (en) Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists
PL353613A1 (en) Application of oestrogen agonist/antagonist in production of a drug
AU2003277215A1 (en) Novel neurokinin antagonists and methods of use thereof
MY143499A (en) Crf receptor antagonist and methods relating thereto
WO2004091546A3 (en) Central nervous system stimulant and opioid antagonist combinations
AU2001239356A1 (en) Method for hydrogenating nitrile functions into amine functions
AU2003274789A1 (en) Handheld terminal, system and method for managing golf scores
AU2001271018A1 (en) Gpr14 antagonist
AU2002352388A1 (en) N-aroyl cyclic amine derivatives and their use as orxin receptor antagonist
AU5404500A (en) Reductive amination of aldehydes
IL175293A0 (en) Pharmaceutical formulation containing an ltb4 antagonist, method for the production thereof, and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase